Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Piminxiao Capsule
- Development stage
- Phase 4
- Lead developer
- Sichuan Defeit Pharmaceutical
- Administration
- Oral
01
Overview
Piminxiao Capsule is a traditional Chinese medicine (TCM) formulation developed by the Jiangsu Province Hospital of Chinese Medicine for the treatment of chronic spontaneous urticaria (CSU). It is specifically indicated for patients presenting with the TCM syndromes of 'wind-heat' or 'wind-heat with dampness.' The capsule is typically used as an adjunctive therapy alongside second-generation H1-antihistamines, such as levocetirizine, to enhance therapeutic efficacy, reduce the Urticaria Activity Score (UAS7), and lower the rate of recurrence. As a botanical product, its pharmacological profile involves multi-target anti-inflammatory and immunomodulatory effects characteristic of its constituent herbs.
- Brand names
- Piminxiao Capsule
- Other names
- Pimin Xiao CapsulePimin Xiao Jiaonang
Beyond the preview
Go deeper on Piminxiao Capsule.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Piminxiao Capsule.